**RE-TREATMENT PATIENT EMAIL TEMPLATE**

Dear **<Patient Name>**,

We haven’t connected with you in a while and wanted to check-in and see how you’re doing after your NeuroStar TMS treatment. We hope you’re doing well, but if you’re still experiencing symptoms of **<choose one: depression / anxious depression / OCD>**, we’d love to help you get back to feeling great and doing the activities you love.

We know for some people, **<choose one: major depressive disorder / anxious depression / OCD>** can be a long-term challenge and additional therapy can be an essential part of the journey to maintain relief. Re-treatment with NeuroStar TMS might be beneficial for you and we offer free follow-up consultations at our office. Simply call us at <Practice Phone #> or reply to this email to schedule.

We hope to hear from you soon.

***<Treater / TMS Coordinator Name>***

**Once you schedule a follow-up consultation, please click the link below and take 2 to 3 minutes to answer the questions.**

**<<Choose one of the below to include in your email:>>**

<<Insert Your Unique PHQ-9 URL here for MDD>>

<<Insert Your Unique GAD-7 URL here for Anxious Depression>>

<<Insert Your Unique Y-BOCS URL here for OCD>>

\_\_\_\_\_\_\_\_\_\_\_\_

The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary.

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).

Visit neurostar.com for full safety and prescribing information.

53-55189-000 Rev B